Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4297832

SUTIMLIMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL4297832
Name SUTIMLIMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Bivv-009 BIVV009 Enjaymo Sutimlimab Sutimlimab jome Sutimlimab-jome TNT-009 TNT009
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
8
Known Names
4
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2022
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

First in Class
USAN Stem -mab

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Complement C1s inhibitor INHIBITOR Complement C1s subcomponent ✓ ✓

Indications

Anemia, Hemolytic, Autoimmune Anemia, Hemolytic, Autoimmune Hemolysis Purpura, Thrombocytopenic, Idiopathic

ATC Classification

L04AJ04
sutimlimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS

Data from ChEMBL 36 via Core Engine